GlaxoSmithKline Dodges a Bullet... for Now

GlaxoSmithKline Dodges a Bullet... for Now


CEO Emma Walmsley got a little welcoming gift from the Food and Drug Administration the week she took the reins of the venerable British healthcare company. Mylan received a notification that its application for a generic version of Glaxo's asthma drug Advair was not approved.



from Biotech News